You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
方盛製藥(603998.SH):1500萬元受讓“恩利卡生在製備治療缺血/再灌注損傷藥物中的應用”的發明專利權
格隆匯 05-10 16:51

格隆匯5月10日丨方盛製藥(603998.SH)宣佈,公司控股子公司湖南恆興醫藥科技有限公司(簡稱“恆興醫藥”)以人民幣1500萬元受讓中南大學持有的“恩利卡生在製備治療缺血/再灌注損傷藥物中的應用”的發明專利權。

該發明公開了恩利卡生(Emricasan)在製備治療缺血/再灌注損傷藥物中的應用。將恩利卡生用於治療缺血/再灌注損傷,尤其是治療腦組織神經病,更尤其是對腦缺血/再灌注的保護作用(缺血性腦卒中),能顯著減輕腦缺血/再灌注損傷。

恩利卡生最初是由Idun Pharmaceuticals研發;2005年4月,輝瑞收購了Idun藥業並獲得該化合物;2010年8月,Conatus Pharmaceuticals(科內圖斯醫藥公司)收購輝瑞的子公司Idun藥業,獲得該化合物的繼續開發權利。

本品相關的藥品研發在國外已進入二期臨牀階段,適應症主要有肝纖維化、門脈高壓症等。中南大學通過研究發現本品對於治療缺血/再灌注損傷方面存在臨牀應用潛力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account